Heron Therapeutics (HRTX) Cost of Revenue (2015 - 2026)

Heron Therapeutics has reported Cost of Revenue for 12 years, with the latest figure at $10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 13.59% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $43.5 million (down 6.27% YoY), and the FY2025 full-year result was $41.3 million, down 12.19% from the prior year.
• Cost of Revenue for Q1 2026 stood at $10.6 million, down from $11.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $21.2 million in Q2 2023, with the low at $8.4 million in Q1 2024.
• Historically, Cost of Revenue has averaged $13.2 million across 5 years, with a median of $11.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 65.88% — and 2023, when it surged 48.43%.
• Heron Therapeutics' Cost of Revenue stood at $17.8 million in 2022, then tumbled by 44.39% to $9.9 million in 2023, then grew by 11.86% to $11.1 million in 2024, then grew by 0.56% to $11.1 million in 2025, then decreased by 4.33% to $10.6 million in 2026.
• The last three Cost of Revenue figures came in at $10.6 million (Q1 2026), $11.1 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.